06/08/11 --
Cytori Therapeutics (NASDAQ: CYTX) is reporting 18 month outcomes from its APOLLO trial for Acute Myocardial Infarction (AMI). The results from the 14 patient, randomized, placebo-controlled, double-blind safety and feasibility trial in patients with ST-elevation AMI demonstrated the following:
- Mean reduction in infarct size at 6 months was preserved at 18 months for the cell treated group (standard-of-care plus cells), at 11.7% and 11.2%, respectively. In contrast, patients receiving control (standard-of-care plus placebo), exhibited diminished treatment effect from 6 months (6.1%) to 18 months (4.4%) (see Fig. 1);
- The mean reduction in left ventricular infarct size (reduction in the portion of the heart damaged by the heart attack) was statistically significant (p < 0.05) from baseline to 18 months in the cell-treated group. In patients receiving control, there was less improvement which was not statistically significant;
- Statistically significant (p < 0.05) improvement in perfusion of the left ventricle (blood flow through the tissue of the heart) from baseline to 18 months was observed in the cell-treated group. In patients receiving control treatment, there was less improvement which was not statistically significant; and
- There were substantially fewer premature ventricular beats (PVBs) per holter recording in patients who had received cells compared to those who had received control (mean of 24 and 146 PVBs per recording, respectively)... Cytori Therapeutics' Press Release -
